Presentation is loading. Please wait.

Presentation is loading. Please wait.

Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization  Robert D. Riley, MD, Hiroki Sato, MD, PhD,

Similar presentations


Presentation on theme: "Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization  Robert D. Riley, MD, Hiroki Sato, MD, PhD,"— Presentation transcript:

1 Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization  Robert D. Riley, MD, Hiroki Sato, MD, PhD, Zhi-Qing Zhao, MD, PhD, Vinod H. Thourani, MD, James E. Jordan, BS, Adolfo X. Fernandez, BS, Xin-Liang Ma, MD, PhD, Duncan R. Hite, MD, Dean F. Rigel, PhD, Theodore C. Pellas, VMD, PhD, Jane Peppard, PhD, Kurt A. Bill, PhD, Rodney W. Lappe, PhD, Jakob Vinten-Johansen, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 120, Issue 2, Pages (August 2000) DOI: /mtc Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

2 Fig. 1 A, Superoxide radical generation by porcine PMNs stimulated by increasing concentrations of rhC5a. B, Concentration responses of C5a-stimulated superoxide radical generation by porcine PMNs and increasing concentrations of CGS *P <.05 versus control. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

3 Fig. 2 A, Stimulation of porcine PMN adherence to porcine coronary artery endothelium by increasing concentrations of rhC5a. B, Inhibition by CGS on adherence of C5a-stimulated porcine PMNs to unstimulated coronary artery endothelium. C5a, PMN stimulated with 100 nmol/L rhC5a, no treatment. *P <.05 versus control. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

4 Fig. 3 Segmental shortening in the ischemia-reperfusion AAR (A) and in the nonischemic zone (B) during the course of the experiment. SAL, Saline solution group; MANN/BUFF, mannitol-buffer vehicle group; CGS, CGS group; CNTL, control or baseline; ISCH, coronary occlusion; BW30, BW60, and BW120, minutes after discontinuation of cardiopulmonary bypass. *P <.05 versus the saline solution and mannitol-buffer vehicle groups. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

5 Fig. 4 Infarct size data as a percentage of either LV mass (in grams) or AAR. A, AAR normalized for mass of the LV; B, area of necrosis (An ) normalized for LV mass; C, area of necrosis normalized for AAR. Open bar, Saline solution group; gray bar, mannitol-buffer group; black bar, CGS group. *P <.05 versus the saline solution and mannitol-buffer vehicle groups. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions


Download ppt "Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization  Robert D. Riley, MD, Hiroki Sato, MD, PhD,"

Similar presentations


Ads by Google